OBJECTIVE: Pulmonary arterial hypertension, characterized by pulmonary vascular remodelling and vasoconstriction, is associated with excessive proliferative changes in pulmonary vascular walls. However, the role of HDACs in the phenotypic alteration of pulmonary arterial smooth muscle cells (PASMC) is largely unknown. MATERIAL AND METHODS: Pulmonary arterial smooth muscle cells were isolated from newborn sheep. Cell cycle analysis was performed by flow cytometry. mRNA and protein expression were measured by real-time PCR and Western blot analysis. Wound-healing scratch assay was used to measure cell migration. Contractility of newborn PASMCs was determined by gel contraction assay. Chromatin immunoprecipitation was used to examine histone modifications along the p21 promoter region. Global DNA methylation was measured by liquid chromatography-mass spectroscopy. RESULTS: Inhibition of class I and class II HDACs by apicidin and HDACi VIII suppressed proliferation of newborn PASMC and induced cell cycle arrest in G1 phase. Acetyl H3 levels were higher in newborn PASMC treated with apicidin and HDACi VIII. This was accompanied by increased expression of p21 and reduced expression of CCND1 but not p53. HDAC inhibition altered histone codes around the p21 promoter region in NPASMC. Apicidin inhibited serum-induced cell migration, and modulated profiling of expression of genes encoding pro-oxidant and antioxidant enzymes. Contractility and global DNA methylation levels of newborn PASMCs were also markedly modulated by apicidin. CONCLUSION: Our results demonstrate that class I HDACs are clearly involved in phenotypic alteration of newborn PASMC.
OBJECTIVE:Pulmonary arterial hypertension, characterized by pulmonary vascular remodelling and vasoconstriction, is associated with excessive proliferative changes in pulmonary vascular walls. However, the role of HDACs in the phenotypic alteration of pulmonary arterial smooth muscle cells (PASMC) is largely unknown. MATERIAL AND METHODS: Pulmonary arterial smooth muscle cells were isolated from newborn sheep. Cell cycle analysis was performed by flow cytometry. mRNA and protein expression were measured by real-time PCR and Western blot analysis. Wound-healing scratch assay was used to measure cell migration. Contractility of newborn PASMCs was determined by gel contraction assay. Chromatin immunoprecipitation was used to examine histone modifications along the p21 promoter region. Global DNA methylation was measured by liquid chromatography-mass spectroscopy. RESULTS: Inhibition of class I and class II HDACs by apicidin and HDACi VIII suppressed proliferation of newborn PASMC and induced cell cycle arrest in G1 phase. Acetyl H3 levels were higher in newborn PASMC treated with apicidin and HDACi VIII. This was accompanied by increased expression of p21 and reduced expression of CCND1 but not p53. HDAC inhibition altered histone codes around the p21 promoter region in NPASMC. Apicidin inhibited serum-induced cell migration, and modulated profiling of expression of genes encoding pro-oxidant and antioxidant enzymes. Contractility and global DNA methylation levels of newborn PASMCs were also markedly modulated by apicidin. CONCLUSION: Our results demonstrate that class I HDACs are clearly involved in phenotypic alteration of newborn PASMC.
Authors: Jayasri Nanduri; Vladislav Makarenko; Vaddi Damodara Reddy; Guoxiang Yuan; Anita Pawar; Ning Wang; Shakil A Khan; Xin Zhang; Brian Kinsman; Ying-Jie Peng; Ganesh K Kumar; Aaron P Fox; Lucy A Godley; Gregg L Semenza; Nanduri R Prabhakar Journal: Proc Natl Acad Sci U S A Date: 2012-01-09 Impact factor: 11.205
Authors: J W Han; S H Ahn; S H Park; S Y Wang; G U Bae; D W Seo; H K Kwon; S Hong; H Y Lee; Y W Lee; H W Lee Journal: Cancer Res Date: 2000-11-01 Impact factor: 12.701
Authors: Tadahiro Shimazu; Matthew D Hirschey; John Newman; Wenjuan He; Kotaro Shirakawa; Natacha Le Moan; Carrie A Grueter; Hyungwook Lim; Laura R Saunders; Robert D Stevens; Christopher B Newgard; Robert V Farese; Rafael de Cabo; Scott Ulrich; Katerina Akassoglou; Eric Verdin Journal: Science Date: 2012-12-06 Impact factor: 47.728
Authors: Qi-Wei Yang; Shuqing Liu; Yufeng Tian; Helen R Salwen; Alexandre Chlenski; Joanna Weinstein; Susan L Cohn Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: Qiwei Yang; Yufeng Tian; Kelly R Ostler; Alexandre Chlenski; Lisa J Guerrero; Helen R Salwen; Lucy A Godley; Susan L Cohn Journal: BMC Cancer Date: 2010-06-14 Impact factor: 4.430
Authors: Lan Zhao; Chien-Nien Chen; Nabil Hajji; Eduardo Oliver; Emanuele Cotroneo; John Wharton; Daren Wang; Min Li; Timothy A McKinsey; Kurt R Stenmark; Martin R Wilkins Journal: Circulation Date: 2012-06-18 Impact factor: 29.690
Authors: Tara V Saco; Prasanna Tamarapu Parthasarathy; Young Cho; Richard F Lockey; Narasaiah Kolliputi Journal: Am J Physiol Cell Physiol Date: 2014-04-09 Impact factor: 4.249
Authors: Eva Nozik-Grayck; Crystal Woods; Robert S Stearman; Sujatha Venkataraman; Bradley S Ferguson; Kalin Swain; Russell P Bowler; Mark W Geraci; Kaori Ihida-Stansbury; Kurt R Stenmark; Timothy A McKinsey; Frederick E Domann Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-05-27 Impact factor: 5.464
Authors: Chunping Zhao; José A Carrillo; Fei Tian; Linsen Zan; Scott M Updike; Keji Zhao; Fei Zhan; Jiuzhou Song Journal: PLoS One Date: 2015-06-18 Impact factor: 3.240